Appili Therapeutics Modifies Acquisition Deal with Aditxt
Company Announcements

Appili Therapeutics Modifies Acquisition Deal with Aditxt

Story Highlights

Appili Therapeutics Inc Class A (TSE:APLI) has released an update.

Appili Therapeutics Inc. announced an amendment to its arrangement with Aditxt, Inc., extending key deadlines and setting new conditions for a planned acquisition transaction. The amendment adjusts the timeline for shareholder meetings, financing, and the completion of a corporate continuation necessary for the acquisition. Appili also settled an $18,000 obligation to its senior secured lender with a cash payment in anticipation of the transaction’s close.

For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAppili Updates on Tularemia Vaccine Progress
TheFlyAppili Therapeutics presents update on ATI-1701 biodefense vaccine candidate
TipRanks Canadian Auto-Generated NewsdeskAppili Therapeutics Corrects Shareholder Payout Terms
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App